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Twenty-eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were
immunized with a peptide homologue of prostate-speciﬁc antigen, PSA146-154, between July 2002 and September 2004 and
monitoredforclinicalandimmuneresponses.Fiftypercent ofthepatientsdeveloped strongPSA146-154-peptide-speciﬁc delayed-
type hypersensitivity skin responses, tetramer and/or IFN-γ responses within one year. Thirteen patients had stable or declining
serumlevelsofPSAoneyearpost-vaccination.Adecreasedriskofbiochemicalprogressionwasobservedinpatientswhodeveloped
augmented tetramer responses at six months compared to pre-vaccination levels (P = .02). Thirteen patients have died while 15
patients remain alive with a mean overall survival of 60 months (95% CI, 51 to 68 months) per Kaplan-Meier analysis. A
trend towards greater overall survival was detected in men with high-risk, hormone-sensitive CaP who developed speciﬁc T-cell
immunity following vaccination with PSA146-154 peptide.
1.Introduction
Prostate cancer (CaP) is the second leading cause of cancer-
related mortality in the United States. There were approx-
imately 27,360 deaths caused by CaP in 2009 [1]. Patients
who recur after primary ablative therapy respond transiently
to androgen deprivation therapy (ADT) but subsequently
progress to hormone-refractory disease for which curative
systemic therapies are lacking [2]. Recent studies have
demonstrated that overall survival (OS) of patients with
hormone refractory CaP can be modestly extended by
vaccinationwithautologousdendriticcells(DC)loadedwith
recombinant proteins consisting of granulocyte macrophage
colony stimulating factor and prostatic acid phosphatase
[3]. It is widely assumed that improved outcomes might
be achieved by vaccinating patients at earlier points in the
development of their disease at a time when host immune
eﬀector mechanisms remain robust.
Prostate-speciﬁc antigen (PSA) contains an HLA-
A2-restricted epitope, PSA146-154, amino acid sequence
KLQCVDLHV,thatis an attractivecandidate forspeciﬁc im-
munotherapy of HLA-A2+ patients with CaP [4, 5]. The
safety and immunogenicity of PSA146-154 peptide vacci-
nation in patients with metastatic, hormone-sensitive CaP,
or a disease that is at high risk of recurrence on the basis
of tumor stage, serum PSA levels, and Gleason score have
been previously reported [6]. Herein, we report the clinical
outcome of patients up to eight years following vaccination
and correlate patients’ survival with their immunological
responses to the PSA146-154 vaccine.2 Clinical and Developmental Immunology
Speciﬁc T-cell responses, deﬁned by PSA146-154 pep-
tide-tetramer staining and IFN-γ r e l e a s ea s s a y s ,w e r eq u a n -
tiﬁed in pre- and postvaccine peripheral blood mononuclear
cells(PBMC) and correlated with clinical parameters includ-
ing biochemicalprogression and OS.In addition, microarray
whole human gene expression analysis was conducted to
identify diﬀerentially expressed genes and gene pathways
in pre-vaccination PBMC that distinguish strong immune
responders from nonresponders.
2.Materialsand Methods
2.1. Patient Characteristics. Long-term follow-up of all pa-
tients previously enrolled on a phase IB peptide vaccine
protocol was performed with the authorization of the
Institutional Review Board of the University of Illinois at
Chicago. Twenty-eight HLA-A2+ patients with pathologi-
cally conﬁrmed CaP who had completed vaccination with
PSA146-154 peptide between July 2002 and September 2004
were included in the study [6]. The clinical characteristics
of patients are listed in Table 1. All patients had undergone
radiotherapy or surgical ablation of the prostate a minimum
of 6 weeks prior to initiation of vaccine study. Patients either
had advanced local disease with high risk of recurrence
based on the presence of T3, T4 disease, a serum PSA level
≥10ng/ml, or a Gleason grade ≥7 (Group A), or they
had conﬁrmed metastatic disease which was associated with
declining serum PSA on ADT or a stable or improving bone
scan or CT scan in response to hormone therapy (Group
B). All patients were immunologically reactive to a panel of
mumps, measles, and candida.
The unique patient identifying number (UPIN) assigned
in the original report was retained. Relevant information
pertinent to morbidity, disease-speciﬁc mortality, and OS
wascollectedfrompatientsand/orfamilymembersfollowing
appropriate informed consent.
2.2. Vaccine Protocol and Dendritic Cell Culture. Patients
were either treated by intradermal administration of native
PSA146-154 peptide and GM-CSF (protocol 1, n = 14) or
byintravenousadministration ofpeptide-pulsed,autologous
DC (protocol 2, n = 14) as previously detailed [6]. Patients
were vaccinated on three occasions (weeks 1, 4, and 10) and
monitored. DC was derived from monocyte and cultured
in serum-free AIM-V (Life Technologies, Grand Island, NY)
medium with IL-4 and GM-CSF for a total of 8 days in T-
150 ﬂasks in clinical grade sterile laminar airﬂow hood per
the method of Lau et al. [7]. Release criteria for the ﬁnal DC
product included sterile bacterial, fungal and mycoplasma
cultures, negative endotoxin per Limulus Amoebocyte lysate
assay, viability of at least 90% and greater than 50% CD86,
CD80, HLA-DR, or CD1a positive cells, and less than 10%
CD 14 positive cells by ﬂow cytometric analysis. The ﬁnal
DCproductwas divided into 3 equalparts. The ﬁrst infusion
included fresh DC while the 2nd and 3rd infusions consisted
of frozen DC product. At the time of infusion, DC were
rapidly thawed at 37◦C, again checked for sterility and via-
bility, and administered intravenously to patients.
2.3. Delayed-Type Hypersensitivity Skin Testing. Immune
responses were monitored by delayed-type hypersensitivity
(DTH)skintesting onweeks 4, 14,26, and 52by intradermal
injection of 0 (carrier only), 1, 10 and 20 microgram of
peptide dissolved in 200 microliter of 33% DMSO as
previously detailed [6]. DTH reactions were measured at 48–
72 hours following injection. An induration of ≥15mm was
considered as a positive reaction.
2.4. T-Cell Culture Induced from Peripheral Blood Mononu-
clear Cells. Frozen PBMC obtained at various study time
points, prevaccine (1 to 3 weeks prior to vaccination), week
26, and week 52, were rapidly thawed, washed, checked for
viability,andresuspended inRPMI-1640medium(BioWhit-
taker, Walkersville, MD) containing 10% human AB serum
(complete medium). Viability was ≥90% (range 90 to 99%,
mean 95±1.26). PBMC (2×106) were plated in 24 well
plates (Nunc, Naperville, IL) and cultured in complete
mediumcontaining PSA146-154peptide (20ug/mL)and IL-
2(20U/mL)for7±1days(1cycle).PBMCwerealternatively
stimulatedwithHLA-A2bindingcontrolpeptide,Flu-M1,in
some patients. Spent medium was aspirated and replenished
with complete medium plus IL-2 and restimulated with
irradiated autologous PBMC pulsed with peptide for 2
additional cycles prior to tetramer and cytokine analysis.
2.5. Tetramer Analysis. PSA146-154 peptide stimulated
PBMC (1×106 per tube) were doubly stained with PSA146-
154 peptide-tetramer-PE (Immunomics, San Diego, CA)
and CD8-FITC (BD Biosciences, San Diego, CA) at room
temperature for 30 minutes in phosphate-buﬀered saline
containing 0.5% para-formaldehyde (Sigma, St. Louis, MO).
Cells were washed, resuspended in buﬀer, and analyzed
by a Calibur ﬂow cytometer (Becton Dickinson, Mountain
View, CA). Cells also were stained separately with a negative
control tetramer-PE, of unknown sequence that does not
recognize CD8+ T-cells of any HLA allele type, to assess the
level of background PE ﬂuorescence. As a positive control,
tetramer-PE staining for Flu-M1 peptide also was performed
in some patients. The percentage of CD8+ tetramer+ cells
was determined from the quadrant dot plots per Cell
Quest software (Becton Dickinson, Mountain View, CA).
The results were represented as the number of tetramer+
cells per CD8+ cells and are calculated as the number of
tetramer+CD8+ cells divided by total number of CD8+ cells.
2.6. Cytokine Bead Array Analysis. PSA146-154 peptide
stimulated PBMC also were evaluated for speciﬁc release of
cytokines following recognition of peptide-pulsed targets.
Cytokines released into the culture supernatant, including,
IFN-γ,T N F - α, IL-4, IL-5, and IL-10, were measured concur-
rently by cytokine bead array analysis (CBA, BD Biosciences,
San Diego, CA) as described earlier [6]. Brieﬂy, the antigen
presenting cell line, T2 (ATCC, Manassas VA), was used
as a stimulator and was pulsed with 20μg/ml of PSA-
peptide or control HLA-A2 binding peptide, HIV-RT476-
484 or diluent alone (0.4% volume by volume). T2 cells
(25,000/well) were cultured with T-cells (100,000/well) inClinical and Developmental Immunology 3
Table 1: Patient baseline characteristics.
Characteristic Group A Group B Protocol-1 Protocol-2 Total
n = 14 n = 14 n = 14 n = 14 n = 28
Age
median (average) 61.5 (62.2) 62 (64) 64.5 (65.2) 60.5 (61) 62
range 51–73 51–80 51–80 51–75 51–80
Race
white 10 13 12 11 23
black 2 1 1 2 3
other 2 0 1 1 2
ECOG PS
0 or 1 14 14 14 14 28
2o r3 0 0 0 0 0
Disease status
undetectable (PSA 0) 3 4 5 2 7
measurable 0 7 2 5 7
increased PSA only 11 3 7 7 14
Sites of disease
bone 0 4 2 2 4
soft tissue 0 4 0 4 4
Family history
positive 4 3 5 2 8
negative 9 9 6 12 17
unknown 1 1 2 0 3
Gleason score
median (average) 7 (7.14) 7 (7.3) 7 (7.2) 7.5 (7.25) 7
range 4–9 5–10 5–10 4–9 4–10
PSA at diagnosis
median (average) 5.8 (9.1) 15.25 (28.4) 8.4 (12.3) 13.4 (24.3) 10.5
range 4–23.4 3.4–139 <4–23.4 3.4–139 3.4–139
PSA at study entry
median (average) 0.32 (3.66) 0.4 (2.6) 0.4 (2.75) 0.4 (3.5) 0.4
range 0–12.5 0–13.8 0–12.1 0–13.8 0–13.8
Local therapy
RPE 2 4 2 4 6
RPE+EBRT 7 4 8 3 11
EBRT, primary 2 4 2 4 6
other 3 2 2 3 5
Hormone Rx
none 10 0 5 5 10
ﬁ r s t l i n e 41 187 1 5
second line 0 2 1 1 2
≥3t h e r a p i e s 0 1 0 1 1
Basal biochemistry
Alkaline phosphatase 48–90 49–105 49–90 50–105 48–105
Haemoglobin 12.8–16.6 11.5–16.9 11.5–15.7 12.2–16.9 11.5–16.9
Creatinine 0.7–1.3 0.8–1.2 0.8–1.3 0.7–1.3 0.7–1.3
All patients had completed primary therapy a minimumof 6 weeks prior to enrollment in the vaccine study.
complete medium containing 30U/ml of IL-2 in a total
volume of 1ml per well in 48-well plates. This particular
stimulator to responder ratio was found to be optimal for
culture in 48-well plates. Cells were incubated at 37◦Cf o r2 4
hours in 5% CO2 atmosphere. Supernatants were harvested
and stored in sterile vials at −80◦C. At the time of assay,
samples were thawed and cytokines were measured using a
CBA kit as per the manufacturer’s protocol with a Calibur4 Clinical and Developmental Immunology
ﬂow cytometer. Results are represented as net cytokine levels
(pg/mL) which were obtained by subtracting nonspeciﬁc
background responses (T2 cells pulsed with HIV-RT476-484
or diluent).
2.7. Microarray and Bioinformatic Analysis. Total RNA was
extracted from unmanipulated prevaccine PBMC samples
of representative patients using RNeasy mini kit (Qiagen,
Valencia, CA). The quantity and quality of RNA were esti-
mated with a NanoDrop 3300 Fluorospectrometer (Thermo
Fisher Scientiﬁc, Waltham, MA) and an Agilent bioanalyzer
(Agilent Technologies, Santa Clara, CA), respectively. All
RNA samples were stored at −80◦C. Microarray analysis
was performed at the functional Genomics Laboratory of
the University of Illinois at Urbana, Champaign, using the
human genome U133 plus2.0 chip (Aﬀymetrix, SantaClara,
CA). Data was extracted from the Aﬀymetrix array and
normalized bytheRobustMultichipAverage(RMA)method
[8]. All appropriate internal quality control was performed
as per the guidelines for microarray gene expression studies.
Class comparison analysis was conducted per the Biometric
Research Branch (BRB) array tool (National Cancer Insti-
tute, Bethesda, MD). Gene expression data was compared
between strong immune responders (UPIN13, UPIN28,
UPIN40, UPIN45, and UPIN71-positive DTH and tetramer
responses) and nonresponders (UPIN32, UPIN35, UPIN37,
and UPIN70-negative DTH and tetramer responses).
2.8. Clinical Evaluation. The disease status of patients was
monitored by clinical examination and serial serum PSA
measurements on weeks 1, 4, 7, 14, 26, and 52. Biochemical
progression (P) was deﬁned as at least a 20% increase in
serum PSA at week 52 over week 1 (study entry) with an
absolute PSA value ≥0.2ng/mL. Stable biochemical disease
or nonprogression (NP) was deﬁned as less than a 20%
increase in serum PSA over week 1 with an absolute PSA
value less than 0.2ng/mL.
Survival status was established for all 28 vaccinated
patients by review of the Social Security Death Registry
Index and by direct contact of patients or their relatives.
Time (in months) from the onset of vaccine therapy (week
1) till death or until May 1, 2010 for patients who were
deceased or surviving, respectively, was calculated followed
by computation of OS per Kaplan-Meier analysis (SAS
software version 9.2, Cary, NC). The median follow-up
period was 6.30 years (mean 5.36 years; range 1.35 to 7.68
years).
2.9. Statistical Analysis. A marginal longitudinal model was
used to compare tetramer or cytokine measurements over
time within similar groups of patients. The dependent
variable was the log of the tetramer values or cytokine mea-
surements. The independent variables included intercept,
group, time dummies, and interactions between group and
time dummies. Spearman analysis was used to evaluate the
correlation of tetramer or cytokines values with serum PSA
status.Thetwo-sample t-test withunequalvariancewas used
to identify genes that were diﬀerentially expressed between
immune responders and nonresponders perBRB array tools.
OS was evaluated per Kaplan-Meier analysis. Log-rank tests
were used to evaluate diﬀerences in survival curves.
3.Results
3.1. Dendritic Cell Product. Two healthy donors and 14
patients underwent 7–9 liter leukapheresis, and DC were
cultured for 8 days under identical conditions and pheno-
typed. The average HLA-DR% was 54.51 (median 52.92),
the average CD86% was 58.77 (median 62.56), the average
CD1a% was 28.17 (median 30.95), and the average CD14%
was 1.31 (median 0 or negative expression). DC product
was also phenotyped for CD80 and CD83. However, only
2 of 14 patients’ DC showed CD80 expression, while CD83
was negative in all the patients. The average percent HLA-
DR, CD86, CD1a, and CD14 were 70.03%, 76.6%, 30.58%
and 5.94%, respectively, in healthy individuals. The yield
of total DC from PBMC ranged from 0.94 to 2.02×108
cells (average 1.499, median 1.555) per vaccine in the
14 patients. Functional activity of DC product also was
tested in several patients. DC, cultured in IL-4/GM-CSF
for 8 days were able to stimulate signiﬁcant (>20-fold)
allogeneic T-cell proliferative responses compared to DC-
pulsed autologous T-cells. Additionally, upon maturation
with TNF-tide induced release of IFN or LPS for 24 hours,
the expression of CD83, a late DC marker, was up-regulated
(negative expression to 25% expression).
3.2. Immunological Responses. Three distinct readouts were
used to detect speciﬁc immune responses. First via the
induction of DTH skin responses to PSA146-154 peptide
in vivo, second via detection of CD8+ PSA146-154 peptide-
tetramer+ T-cells, andthirdviaPSA146-154peptideinduced
release of IFN-γ in pre- versus postvaccine PBMC samples.
In vitro sensitization of PBMC with PSA146-154peptide was
essential prior totetramer andCBAanalysis todetectspeciﬁc
T-cells in peripheral blood. This procedure was applied
uniformly to all specimens and was necessary to overcome
high background. Similar techniques have been employed in
previous cancer vaccine trials [7, 9]. Lau et al. have shown
induction of peptide-speciﬁc CTL stimulated twice with
melanoma-associated peptides over 24 days in IFN-γ ELISA
[7]. Meidenbauer et al. have shown PSA-reactive responses
per IFN-γ ELISPOT following two stimulations in patients
with prostate cancer [9].
Overall, ﬁfty percent of patients demonstrated positive
DTH skin responses to PSA146-154 peptide (Table 2). Spe-
ciﬁc DTH responses were negative in a majority of patients
(13 of 14 patients) when they were tested initially at week
4; however, measurable induration became evident over
time and increased with successive DTH testing. Responses
were dose-dependent with increasing doses of the PSA146-
154 peptide eliciting increasing degrees of induration in
responding patients[6].Injectionofcarrieronly,thatis,33%
DMSO, did not cause signiﬁcant induration. Both CD4+
and CD8+ T-cells were derived from the positive DTH skinClinical and Developmental Immunology 5
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Figure 1: A representative ﬂow cytometric data showing the detection of CD8+ PSA146-154 peptide-tetramer+ cells in patient UPIN28.
PBMC were sensitized in vitro with PSA146-154 peptide for 3 cycles, and resulting T-cells were doubly stained with PSA146-154 peptide-
tetramer-PE ((c) and (d)) or negative control tetramer-PE ((e) and (f)) and CD8-FITC ((e), (f), (c), and (d)). A greater number of CD8+
PSA146-154 peptide-tetramer+ cells ((a) and (b)) were observed on postvaccine compared to prevaccine samples.6 Clinical and Developmental Immunology
Table 2: Immunological outcomes based on speciﬁc DTH, tetramer, and IFN-γ responses.
Patient
Code
DTH
responders
positive (+)
negative (−)
Fold increase in tetramer
Tetramer
responders
positive (+)
negative (−)
Absolute change in IFN-γ
IFN-γ
responder
positive (+)
negative (−)
week 26 week 52 week 26 week 52
UPIN13 + 22.25 34.49 + 141.4 0 +
UPIN16 + 22.77 121.29 + 44.4 241.6 +
UPIN28 + 29.25 12.5 + 525.4 847.9 +
UPIN40 + 15.85 2.47 + 313.5 488.9 +
UPIN45 + 11.39 6.97 + 30.6 88.8 −
UPIN49 + 1.75 1.71 − 0 113.5 +
UPIN50 + 6.11 3.8 + −20.7 −20.7 −
UPIN51 + 0.69 0.26 − 00−
UPIN53 + 1.58 0.69 − 25.3 2417.4 +
UPIN55 + 2.71 5.28 + 262.7 66 −
UPIN69 + 2.09 0.23 − 1293.5 133.4 +
UPIN71 + 4.91 4.82 + 20.9 31 −
UPIN81 + 1.72 0.09 −− 2.9 −2.9 −
UPIN88 + 1.42 0.06 −− 34.5 230.4 +
UPIN2 − 3.09 5.83 + 63.9 −50.2 −
UPIN21 − 0.51 5.43 + 1064 −9.3 +
UPIN26 − 0.35 0.81 − 255.5 1211.4 +
UPIN27 − 82.11 ND + 2236 ND +
UPIN32 − 1.13 1.05 − 00−
UPIN35 − 1.31 0.09 −− 10.4 24.3 +
UPIN37 − 0.80 0.26 − 1.4 0 −
UPIN38 − 10.79 1.37 + 112.1 1.3 +
UPIN43 − 1.11 5.06 + −3.5 −11.2 −
UPIN67 − 1.72 0.07 − 40.3 0 −
UPIN70 − 0.46 1.85 − 130.9 0 +
UPIN82 − 4.47 0.24 + −3.2 −3.2 −
UPIN85 − 2.50 0.08 − 00−
UPIN89 − 2.93 0.02 −− 46.9 −46.9 −
Fourteen of 28 (50%) patients developed positive tetramer, IFN-γ, and/or DTH responses to PSA146-154 peptide by week 52. A positive tetramer response is
deﬁned as ≥4-fold increase in tetramer levels by week 52 over prevaccine levels, while positive IFN-γ response was deﬁned as ≥100ng/ml of absolute change
in cytokine levels at week 26 or 52 minus prevaccine levels. A positive DTH reaction is deﬁned as ≥15mm of induration to PSA146-154 peptide. A stringent
cutoﬀ value was taken into consideration to measure true immune responses and to avoid false positives.
biopsy that demonstrated speciﬁc cytolytic and cytokine
activity as detailed in a previous publication [6].
Fourteen of 28 patients developed ≥4-fold increase in
CD8+ PSA146-154-tetramer+ T-cells at week 26 and/or
week 52 over baseline levels (Table 2). On average, 3.5 CD8+
PSA146-154-tetramer+ T-cells were observed for every 100
CD8+ T-cells at week 26, while an average of 2.0 CD8+
PSA146-154-tetramer+ T-cells were detected for every 100
CD8+ T-cells at week 52. On an average, 1.0 CD8+ PSA146-
154-tetramer+ T-cell could be detected per 100 CD8+ T-
cells prior to the onset of immunotherapy. Figure 1 is a
representative tetramer staining analysis showing increased
CD8+ PSA146-154-tetramer+ T-cells postvaccine (week 26)
compared to prevaccine following in vitro sensitization
of PBMC with PSA146-154 peptide. Tetramer responses
were not detectable in unstimulated PBMC population.
Comparable results were observed by Lau and coworkers in
a peptide-DC based melanoma study [7].
Similarly, 14 of 28 patients demonstrated speciﬁc release
of IFN-γ (deﬁned as ≥100ng/ml of absolute change) by
week 52 from the outset of immunotherapy. Speciﬁc release
of other cytokines, namely, TNF-α, IL-4, and IL-5 also was
observed (see Table 1 in supplementary material available
online at doi:10.1155/2010/473453).The CBA analysis in the
current study was performed with unsorted T-cell popula-
tions; therefore, it is not possible to determine whether IFN-
γ was released by CD8+ and/or CD4+ T-cells.
Eight of 14 (57%) positive tetramer responders also
mounted speciﬁc DTH responses to PSA146-154 peptide,
while only 4/14 (28%) tetramer nonresponders were positiveClinical and Developmental Immunology 7
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Figure 2: Correlation between augmented-speciﬁc tetramer
responses and serum PSA status. The average tetramer mea-
s u r e m e n t sa tw e e k2 6m i n u sp r e v a c c i n el e v e l s( Δ26) inversely
correlated with lower risk of serum PSA progression at six months
following the onset of immunotherapy (P = .02). “NP” denotes
stable biochemical disease or nonprogression, while “P” denotes
biochemical progression.
for DTH responses to the peptide, indicating concordance
between the developmentofpeptide-speciﬁc DTH responses
in the skin and speciﬁc T-cell immune responses in periph-
eral blood of patients.
3.3. Clinical Outcomes: Toxicity, Serum PSA, and
Survival Status
3.3.1. Toxicity. Both methods of vaccination were well toler-
ated with no treatment-related grade 3/4 toxicities, graded
according to the NIH Common Terminology Criteria for
AdverseEvents,version3.0.Mildpain,itching,anderythema
withorwithouttransientindurationwereobservedatthesite
of injection for all patients treated under protocol-1. There
have been no late safety concerns or deleterious sequelae
identiﬁed after six to eight years of monitoring.
3.3.2. PSA Progression. Thirteen of 27 (48.1%) patients
manifested stable or declining serum PSA, while 14 of 27
(51.6%) patients evidenced PSA progression at one year
following the initiation of PSA146-154 peptide vaccine
therapy. One patient, UPIN27, did not return for follow-
up at week 52 and hence his biochemical status was not
evaluable. However, the survival status was determinable in
all 28 patients. As of May 1 2010, 15 of 28 (54%) patients
werealivewhile13(46%)patientshaddied.Inmostpatients,
death was CaP speciﬁc; however, one patient, UPIN16, died
of late occurring esophageal cancer.
3.3.3. Survival. OS is the most deﬁnitive standard to assess
the outcome of anticancer therapies and was determined
per Kaplan-Meier analysis eight years after the initiation of
the protocol. The median follow-up period for individual
patients was 6.30 years (range 1.35 to 7.68 years) from the
onset of immunotherapy. The mean OS was 60 months
(95% CI 51 to 68 months) for all patients (Figure 3(a)).
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Figure 3: Overall Survival for high risk, locally advanced and
metastatic hormone-sensitive CaP. The mean OS was 60 months
(95%CI 51 to 68 months) for all patients (a). The median OS was
greater than 84 monthsfor patients with high risk, locallyadvanced
disease (b), while the median OS was 75 months for patients with
metastatic,hormone-sensitiveCaP(c)atamedianfollow-upof6.30
years since the onset of immunotherapy.
The median OS has not yet been reached for patients with
high risk, locally advanced disease and exceeds 84 months,
Figure 3(b). The median OS was 75 months for patientswith
metastatic, hormone-sensitive CaP (Figure 3(c)).
3.4. Correlation of Clinical Outcome with the Induction of
Speciﬁc Immune Responses. The development of speciﬁc
T-cell immune responses wascorrelated with patients’serum
PSA and survival status. The results indicate that the
diﬀerence between average tetramer measurements at week
26 and at baseline inversely correlated with changes in serum
PSA levels (Figure 2, P = .02). Thus, a decreased risk of bio-
chemical progression was observed in patients who devel-
opedaugmented tetramer responses atsix months compared
topre-vaccinationlevels.Nosigniﬁcantcorrelationremained8 Clinical and Developmental Immunology
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Figure 4: Comparison of overall survival between immune respon-
ders versus nonresponders. There was a trend towards greater OS
in men with high-risk, hormone-sensitive CaP who developed
strong speciﬁc DTH or tetramer response following vaccination
with PSA146-154 peptide.
at one year, as speciﬁc immune responses became attenuated
over time.
OS of patients who developed positive DTH responses,
tetramer or, IFN-γ responses to PSA146-154 peptide versus
that of patients who did not develop speciﬁc immune
responses were correlated by log-rank testing. The mean OS
w a s5 8m o n t h s( 9 5 %C I ,5 0t o6 6m o n t h s )f o rs t r o n gD T H
responders versus 54 months (95% CI, 41 to 68 months)
for nonresponders (P = .21). The mean OS was 61 months
(95% CI, 50 to 71 months) in patients who showed strong
tetramer responses versus 44 months (95% CI, 35 to 52
months) for nonresponders (P = .46). The mean OS was 61
months (95% CI, 50 to 73 months) in patients who showed
strong IFN-γ responses versus 55 months (95%CI, 43 to
68 months) for nonresponders (P = .65). Although these
ﬁndings did not reach statistical signiﬁcance, the patients
who developed strong T-cell immunity in terms of speciﬁc
DTH and tetramer responses to PSA146-154 peptide within
oneyearfollowingvaccinationdemonstratedatrendtowards
greater OS (Figure 4).
3.5. Gene Expression Proﬁles of Immune Responders versus
Nonresponders. Aﬀymetrix human genome U133 plus 2.0
c h i p sa r r a ya n a l y s i sw a sp e r f o r m e do np r e v a c c i n eP B M C ,
in order to identify genes and gene pathways that are
diﬀerentially expressed between patients who developed
strong PSA146-154 peptide-speciﬁc immune responses ver-
sus patients who did not. Immune responders included
patients with strong tetramer (>4.9 fold) responses in
conjunction with a positive DTH skin reaction to the
PSA146-154 peptide, while nonresponders included patients
who were negative for both tetramer and DTH responses.
Class comparison analysis per BRB array tools revealed
that 166 of 54,675 genes were diﬀerentially expressed at a
signiﬁcance level of P<. 005 (Supplemental Table 2). Pre-
dictably, the gene ontology class belonging to the biological
process category of immune system development (GO
ID: 0002520) was aﬀected with an observed to expected
ratio of 2.1. Of the 166 diﬀerentially expressed genes, 12
genes were members of the immune function associated
pathway (Table 3). A 4-fold increase in 2 –5  oligoadenylate
synthetase 1 (OAS1) was noted in immune responders
versus nonresponders. Other genes that were overexpressed
included mitogen-activated protein kinase 1, Sh2 domain
containing 1B, vannin 1, CD58 molecule, and interferon-
induced transmembrane protein-3. Tumor necrosis factor
receptor superfamily-member 25, chemokine C-C motif
receptor 7 and phosphoinositide-3-kinase, regulatory sub-
unit 1 alpha genes, and epiregulin showed lower expression
in immune responders versus nonresponders.
4.Discussion
The ﬁeld of cancer immunotherapy recently reached an
exciting milestone with the approval of the ﬁrst therapeu-
tic cancer vaccine by the United States Food and Drug
Administration. Sipuleucel-T (Provenge), an autologous
cellular immunotherapeutic product that is designed to
stimulate T-cell immunity to prostatic acid phosphatase, was
found to improve the median overall survival of patients
with metastatic, castration resistant CaP by 4.1 months
(25.8 versus 21.7 months for placebo) [3, 10]. Similarly,
immunotherapy with PROSTVAC-VF, a PSA-based viral
vaccine construct, also improved survival in a phase 2
trial for patients with metastatic, castration-resistant CaP
[11]. These studies have highlighted the potential of speciﬁc
immunotherapy for the management of patients with CaP.
To date, the majority of tumor vaccines have been
evaluated in patients with the most advanced forms of
disease. In the current study, we observed the development
of speciﬁc T-cell immunity in terms of increased peptide-
speciﬁc tetramer and IFN-γ responses (≥4-fold increase
or ≥100pg/ml fold change, resp.) in 50% of patients
vaccinated at points in the spectrum of prostate cancer thatClinical and Developmental Immunology 9
Table 3: Diﬀerentially expressed genes between immune responders and nonresponders∗.
Gene name (symbol) Probe set Fold change Aﬀected immune-function associated
pathway
2 –5  oligoadenylate synthetase 1 (OAS1) 202869 at
205552 s at
4.05
2.48 Innate immune response
Vannin 1 (VNN1) 205844 at 2.74
Innate immune response
Positive regulation of T-cell
diﬀerentiation in the thymus
Sh2 domain containing 1B (SH2D1B) 1553176 at 1.92 Natural killer cell mediated cytotoxicity
DEAD box polypeptide 58 (DDX58) 218943 s at 1.82 Innate immune response
Interferon-induced transmembrane
protein 3 1–8U (IFITM3) 212203 x at 1.55 Immune response
Mitogen-activated protein kinase 1
(MAPK1)
1552263 at
1552264 a at
1.53
1.37
T-cell and B-cell receptor signaling
VEGF signalingpathway TGF-beta
signaling
natural killer mediated cytotoxicity
CCR3 signalingin eosinophils
CXCR4 signaling pathway
CD58 molecule (CD58) 216942 s at
205173 x at
1.46
1.48 IL-17 signalingpathway
X-ray repair complementing defective
repair in Chinese hamster cells 4
(XRCC4)
210813 s at 1.38 T-cell diﬀerentiation in the thymus
Immunoglobulin V(D)J recombination
Tumor necrosis factor receptor
superfamily, member 25 211841 s at 0.65 Cytokine-cytokine receptor interaction
Chemokine C-C motif receptor 7 (CCR7) 206337 at 0.52 Cytokine-cytokine receptor interaction
Phosphoinositide-3-kinase,regulatory
subunit 1 alpha (PIK3R1) 212249 at 0.62
T-cell activation
T-cell and B-cell receptor signaling
CXCR4 signaling pathway
VEGF signaling pathway
Toll-like receptor signalingpathway
Epiregulin (EREG) 205767 at 0.26 positive regulation of innate immune
response
Gene expression analysis was performed on unmanipulated pre-vaccination PBMC. ∗Of the 166 genes diﬀerentially expressed, only genes aﬀecting the
immune function associated pathway are shown.
precede the development of castrate-resistance. Importantly,
patients who developedaugmented tetramer responses at six
months compared to pre-vaccination levels had a decreased
risk of biochemical progression at one year following the
onset of immunotherapy. The inclusion of patients with
hormone-sensitive disease who are immunologically robust,
as reported here, may be key to harnessing the full potential
of novel vaccine regimens.
In the current study, 15 of 28 (54%) patientswere alive at
eightyears fromthe initiation oftheprotocolwhile 13(46%)
patientshaddied.Ofnote,atrendtowardsgreatersurvival in
men with high-risk, hormone-sensitive CaP who developed
strong speciﬁc DTH or tetramer responses following vacci-
nationwithPSA146-154peptidewasobserved.Twoprevious
cancer vaccine studies conducted in hormone-refractory
CaP patients showed that survival positively correlated with
the induction of speciﬁc immune responses [12, 13]. The
demonstration of statistically signiﬁcant survival advantages
by immunization of hormone-sensitive CaP patients with
longer life expectancies will require extended periods of
observation and expanded patient cohorts.
The availability of quantitative metrics for monitoring
the induction of speciﬁc T-cell immunity to deﬁned target
antigens as in the present study should provide an important
surrogate for gauging vaccine eﬃcacy, if a causal relationship
between the induction of speciﬁc T cell immunity and
survival advantages can be deﬁnitively established. This in
turn would speed vaccine optimization for early phases
of CaP. It also is critical to establish formal standards
for reporting immunomonitoring in clinical trials to avoid
variations between laboratories and also among various
assays. However, this will entail storage of large amounts of
samples to ensure the ability to conduct validating studies
and retrospectively apply emerging assays that become
relevant over time.
DC are central to successful vaccination and can be
directly targeted in vivo with antigen and adjuvants, such as
GM-CSF, as demonstrated in early pioneering studies [14–
16]. Alternatively, ex vivo generated monocytic or CD34-
derived DC loaded with tumor antigen can be utilized for
speciﬁc active immunotherapy of cancer patients [17–20].
However, DC-based vaccine formulations involve laborious10 Clinical and Developmental Immunology
manipulations ex vivo and incur considerable cost. In the
current study, the eﬃcacy of PSA146-154 peptide vaccine by
bothtechniques was compared in a randomized fashion. The
ﬁnding that a simple method of intradermal vaccination is
eﬃcacious has important implications for the aﬀordability
and applicability of the technique to the general population.
These results were corroborated by a similar study, wherein,
intradermal injection of E75 HER2/neu peptide plus GM-
CSF was found to be eﬃcacious in high-risk node positive
breast cancer patients [21].
The present study shows for the ﬁrst time, that a set
of molecular determinants expressed within PBMC distin-
guish immune responders and nonresponders undergoing
vaccination with a peptide-based cancer vaccine. Genomic
and bioinformatics analysis revealed 166 genes that were
diﬀerentially expressed between strong immune responders
versus nonresponders. In particular, genes associated with
innate immune response were over-expressed, including,
OAS1, which belongs to a family of IFN-stimulated proteins
[22]. Interestingly, OAS1 also is postulated to be associated
with radiation resistance in human breast cancer and CaP
cell lines and with the regulation of cell growth in mammary
and prostate glands [23, 24]. Understanding the molecular
intricacies of why some patients respond to a well deﬁned
peptide target, while others do not, should lead to the
application of optimal vaccine strategies for appropriately
selected patients and shed light on novel strategies to make
targeted immunotherapy applicable to a wider array of
patients.
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